Original article
10 years of AMNOG (Medicines Market Reorganization Act) is an occasion for many individual and institutional status reports. In a UCEF workshop in Rostock (Independent Center for Market and Social Research), representatives from the areas of health policy, market access and reimbursement brought together their experiences on product evaluations.
01.02.2021
The Janssen Open House, which took place digitally for the first time this year, once again offered a 360-degree perspective on medically relevant topics of the present and future. The participants of the #JOH2020 received innovative and visionary impulses, but also experienced an intensive exchange - despite the purely virtual format. Among those present was Dr. Paul Stoffels, global head of research at Johnson & Johnson, who presented Janssen's research activities, including in relation to Covid-19.
01.02.2021
Die medikamentöse Behandlung der Rheumatoiden Arthritis wurde in den letzten beiden Jahrzehnten um zwei neue Arzneimittelgruppen erweitert und bietet den Ärzten zusätzliche Therapieoptionen. Doch welche Empfehlungen zur Pharmakotherapie gibt es, wie sieht die Arzneimitteltherapie in der Praxis aus und wohin entwickelt sich diese möglicherweise weiter? Diese Fragen werden im folgenden Beitrag durch die Darstellung einzelner Aspekte in Ansätzen beleuchtet.
01.02.2021
In 2016, the Bertelsmann Foundation published a representative study in which 91 percent of those surveyed were in favor of medical practices, hospitals and care facilities being required by law to clearly disclose their quality (Bertelsmann Foundation, 2016). This clear result shows that citizens demand accountability from healthcare providers about the quality of their work, regardless of what other possible positive effects may come with quality transparency. These effects are diverse and work on different levels (see Fig. 1). The publication of quality data is intended to stimulate quality competition by directly motivating service providers to improve quality - on their own professional initiative and/or based on mutual observation. This is not only shown by international studies (Kumpunen, Trigg & Rodrigues, 2014); The publication of quality reports by hospitals, which has been legally required since 2005 (Section 136b Paragraph 1 No. 3 SGB V), has also led to improvements in many of the published indicators (IQTIG, 2019). But transparency also ensures that patients are supported in their choices. Furthermore, performance and quality data can be used as a basis for the control and planning of provider structures in the healthcare system. However, this is not actually happening yet.
01.02.2021
Rare diseases form a heterogeneous group of mostly complex clinical pictures. They often take a chronic course, accompanied by disability and/or reduced life expectancy, and often lead to symptoms as early as childhood. About 80% of the rare diseases are genetic or partly caused, they are rarely curable (BMG 2019) (Orphanet 2020) (Fig. 1). Due to the rare occurrence of familial hypophosphatemic rickets - including XLH - and the insufficient data in Germany, the aim of this health services research was to collect epidemiological data and to present the health care situation and pharmacoepidemiology of patients with a confirmed E83.30 ICD-10 diagnosis. For the retrospective analyses, routine data and billing data from statutory health insurance (GKV) were used, which are becoming increasingly important in health services research (Neubauer et al. 2014).
01.02.2021
„Gesundheit 2025 – 2 x 5 Thesen und Forderungen“ nennt ein Autoren-Sextett1 ein in einem Pre-Release der Medizinisch Wissenschaftlichen Verlagsgesellschaft (MWV) Ende 2020 erschienenes Whitepaper mit dem Titel „Corona Future Management“2. Ihrer persönlichen Ansicht nach hat das Gesundheitssystem in Deutschland unter Beweis gestellt, dass es im Krisenfall eine hohe Koordinierungs- und Veränderungsdynamik entfalten könne. Nun werde die Aufgabe für die Zukunft sein, diese „neu gelebte Schnelligkeit und Pragmatismus auch in Zukunft – außerhalb von Krisenzeiten – zu bewahren.“
01.02.2021
„"The symptom that prompted a user to see a doctor or use the Ada app doesn't, in itself, determine how urgently medical help is needed." This statement from the interview with Dr. Andreas Gilsdorf is particularly relevant in times of COVID-19: A cough and runny nose usually indicate a flu-like infection, but only usually. A good doctor can provide more precise information after a more detailed medical history, but—if, as in some countries, one isn't readily available—an app like Ada Health can also help. According to Gilsdorf, Ada Health "introduces a kind of care triage based on a probability level as well as the type and severity of the reported symptoms.".
01.02.2021
In an open-access article published in the BMJ's Evidence-Based Medicine journal, titled "From publication bias to lost in information: why we need a central public portal for clinical trial data," two IQWiG employees, Beate Wieseler and Natalie McGauran, call for a central public portal for clinical trial data. The authors state that this should be understood as "a proposal to ensure efficient and complete access to clinical trial data.".
01.02.2021
Anyone who hears or reads the name OptiMedis automatically thinks of Dr. h.c. Helmut Hildebrandt, the co-founder of the healthcare management, analytics, and research company. For years, he has been a tireless advocate, indeed a champion, of cross-sectoral care models, and the company now encompasses far more than just the initial "Healthy Kinzig Valley" project. However, the fact that OptiMedis does much more—particularly in healthcare research—is not yet widely known. Dr. Oliver Gröne, PhD MSc, Deputy CEO of OptiMedis AG, describes the background and key areas of focus. He is responsible for Analytics, Research & Innovation, and Organization.
01.02.2021
At the online conference „Structural Migration through Complex Intervention“ organized by IGiB StimMT at the end of last year, three workshops addressed the following topics: the „Economic Dimensions of Outpatient Care“ (Part 1, MVF 06/20), the „Evaluation of Complex Interventions“ (to be published in MVF 02/21), and the „Advantages and Drawbacks of Managing Large-Scale Innovation Fund Projects.“ This part of the report trilogy focuses on this latter topic.